An American biotechnology company announced positive results from a clinical trial of its GLP-1: a 68% reduction in liver fat. American biotechnology company MetaVia presented interim data from phase I clinical trials (CT) of the glucagon-like receptor (GLP-1) drug DA-1726. The study showed that after 16 weeks of taking the drug once a week, the fat content in the liver decreased by 68% compared to the placebo. At the same time, in patients who received the drug, the decrease in body weight was 13.5%. * During Phase I, DA-1726 was tested in 15 healthy obese adult patients, and four additional participants received placebo. MetaVia CEO Hyun Hong Kim noted that the drug DA-1726 has potential as a cardiometabolic therapy targeting the liver. The biotech intends to begin a 48-week phase II study in up to 150 patients with autoimmune liver disease in the second half of 2027. "We intend to build on these results by promoting a program for the treatment of metabolic dysfunction and alcohol-related liver disease (METALD) and alcohol-related liver disease (ALD), for which there are currently no approved treatments," Kim said, adding that over 16 weeks the drug improved three indicators: liver fat content, body weight and glycated hemoglobin level. Read us in Max Telegram VK.